Zacks: Analysts Expect Dimension Therapeutics, Inc. (DMTX) to Announce -$0.49 EPS
Brokerages forecast that Dimension Therapeutics, Inc. (NASDAQ:DMTX) will post ($0.49) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Dimension Therapeutics’ earnings. Dimension Therapeutics reported earnings of ($0.58) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 15.5%. The business is scheduled to issue its next quarterly earnings results on Thursday, November 9th.
On average, analysts expect that Dimension Therapeutics will report full year earnings of ($1.99) per share for the current financial year. For the next year, analysts expect that the company will report earnings of ($1.50) per share, with EPS estimates ranging from ($2.20) to ($0.80). Zacks Investment Research’s EPS averages are an average based on a survey of research firms that follow Dimension Therapeutics.
Dimension Therapeutics (NASDAQ:DMTX) last announced its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.49). The firm had revenue of $4.37 million for the quarter. Dimension Therapeutics had a negative return on equity of 98.72% and a negative net margin of 358.21%.
DMTX has been the subject of a number of research analyst reports. ValuEngine raised shares of Dimension Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday. Canaccord Genuity decreased their target price on Dimension Therapeutics from $20.00 to $12.00 and set a “buy” rating on the stock in a research report on Wednesday, June 28th. Citigroup Inc. raised Dimension Therapeutics from a “sell” rating to a “neutral” rating and lifted their target price for the stock from $5.50 to $6.00 in a research report on Tuesday. Zacks Investment Research lowered Dimension Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, July 10th. Finally, Wells Fargo & Company lowered Dimension Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Tuesday. Two analysts have rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $4.23.
Several hedge funds have recently made changes to their positions in DMTX. Weiss Multi Strategy Advisers LLC lifted its holdings in shares of Dimension Therapeutics by 6.7% during the 1st quarter. Weiss Multi Strategy Advisers LLC now owns 390,403 shares of the biotechnology company’s stock worth $683,000 after acquiring an additional 24,489 shares during the period. Two Sigma Securities LLC acquired a new stake in shares of Dimension Therapeutics during the 1st quarter valued at about $108,000. Finally, Goldman Sachs Group Inc. boosted its position in shares of Dimension Therapeutics by 206.7% during the 2nd quarter. Goldman Sachs Group Inc. now owns 80,471 shares of the biotechnology company’s stock valued at $117,000 after acquiring an additional 54,231 shares in the last quarter. Institutional investors own 70.75% of the company’s stock.
Dimension Therapeutics (NASDAQ:DMTX) traded up 0.85% during trading on Tuesday, reaching $5.95. 203,565 shares of the company’s stock were exchanged. The company’s market capitalization is $149.06 million. The stock’s 50-day moving average price is $3.86 and its 200-day moving average price is $2.02. Dimension Therapeutics has a 52-week low of $1.05 and a 52-week high of $8.00.
Dimension Therapeutics Company Profile
Dimension Therapeutics, Inc is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dimension Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dimension Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.